The U.S. Department of Health and Human Services unveiled a blueprint to speed and streamline early clinical development, targeting first-in-human timelines of 6–12 months shorter. The package includes FDA guidance changes aimed at reducing unnecessary documentation and making IND processes more flexible for protocol adjustments. HHS is also proposing a pilot program to connect developers with a network of research institutions for IND preparation, plus a “rolling submission” concept for timely FDA feedback. The plan reflects growing pressure to maintain U.S. leadership as companies increasingly start trials faster abroad. The blueprint also signals potential changes in how trial enrollment logistics are handled, including exploration of stipends for enrollees alongside reimbursement of health insurance cost-sharing under anti-kickback rules. With early-stage acceleration at the center, the initiative is expected to influence how sponsors design toxicology packages, data readiness milestones, and the operational flow from candidate selection to IND filing.